Zovegalisib now carries Relay's whole story
- Relay has no approved product yet, so the stock depends on clinical trial results.
- Zovegalisib is the lead drug, aimed first at PIK3CA-mutant HR+/HER2- breast cancer.
- The FDA granted Breakthrough Therapy designation for zovegalisib plus fulvestrant in February 2026.
- The Elevar licensing deal moved lirafugratinib off the balance sheet and kept focus on zovegalisib.
- A May 2026 public offering raised $296.8 million, extending the cash runway for Phase 3 trials.
One lead drug, clearer focus
Relay is a pre-commercial biotech. That means it is still trying to prove its drugs work and can be approved. Its main asset is zovegalisib, also called RLY-2608, a PI3Kα inhibitor being tested in PIK3CA-mutant HR+/HER2- advanced breast cancer.
The bull case improved after Relay made key strategic and financial moves. First, it licensed lirafugratinib to Elevar in December 2024, which reduced the need to fund that drug alone. Second, zovegalisib plus fulvestrant received FDA Breakthrough Therapy designation in February 2026, a status meant to speed development for drugs that may offer a major improvement. Third, a May 2026 public offering generated $296.8 million in net proceeds, partially mitigating concerns over capital intensity.
Relay also widened the zovegalisib story. It is running the Phase 3 ReDiscover-2 trial, testing a triplet with fulvestrant and Pfizer's atirmociclib, and studying zovegalisib in PROS, a disease driven by PIK3CA mutations. In May 2026, the company shared initial clinical data from the ReInspire trial showing potential differentiated safety and efficacy for PROS.
The bear case remains focused on realization. Relay has never brought a drug to market, and its platform still has to prove that better drug design leads to approved drugs and real sales. If zovegalisib misses in Phase 3, the company loses its main near-term path to value.
Milestones before medicine sales
Relay does not yet sell an approved medicine. It generates occasional license revenue, but it consistently reports significant net losses. Most spending goes to research, trials, staff, and public company costs.
The current model is to raise money, run trials, and use partners when that helps fund the pipeline. The Elevar deal brought milestone payments and the potential for up to $485.0 million in future regulatory and commercial milestones, plus tiered royalties, if lirafugratinib succeeds under Elevar.
Relay also uses the stock market to fund itself. It completed a major public offering in May 2026, raising $296.8 million in net proceeds. This added to cash reserves and ensures trials like ReDiscover-2 can continue.
Where the model breaks is funding exhaustion. If trials take longer, fail, or require larger studies, Relay may need more cash before it has product sales. That can mean more stock sales, more partnerships, or cutting programs.
Pipeline around PI3Kα
Zovegalisib plus fulvestrant
This is Relay's lead breast cancer program and the center of the Phase 3 ReDiscover-2 trial. The FDA granted Breakthrough Therapy designation for this combination in February 2026.
Zovegalisib triplet with atirmociclib
Relay is testing zovegalisib with fulvestrant and Pfizer's atirmociclib, an investigational selective CDK4 inhibitor. The goal is to see if a three-drug plan can improve outcomes in the same broad breast cancer setting.
Zovegalisib for PROS
Relay started a global Phase 1/2 trial for PIK3CA-related overgrowth spectrum, or PROS, and vascular anomalies driven by PIK3CA mutations. Initial clinical data arrived in May 2026.
Lirafugratinib
Lirafugratinib, also called RLY-4008, is an FGFR2 inhibitor licensed globally to Elevar. Relay no longer carries the full development burden, but it may still benefit through milestones and royalties.
RLY-8161
RLY-8161 is an NRAS-selective inhibitor being studied in NRAS-mutant solid tumors. It is earlier than zovegalisib and still needs clinical proof.
Fabry disease chaperone
Relay is advancing a non-inhibitory chaperone for Fabry disease. This keeps the platform tied to genetic disease, but the program is still early.
Spend, not sales
Relay does not report product revenue segments because it has no approved medicine. The mix below uses operating expense categories to show where the company spends money, rather than where it earns revenue.
What can break the thesis
ReDiscover-2 misses
High impact · Medium oddsZovegalisib is the main value driver. If the Phase 3 ReDiscover-2 trial does not show clear safety and efficacy against capivasertib plus fulvestrant, the Breakthrough Therapy designation will not matter much. A miss would also raise doubts about the Dynamo platform.
Safety limits the dose
High impact · Medium oddsPI3K pathway drugs can be hard to dose because side effects can hurt daily use. Relay's case depends on zovegalisib keeping a good balance between tumor control and tolerability. If patients stop treatment often, the drug could lose its edge.
Capital needs dilute holders
Medium impact · High oddsRelay expects significant losses for at least the next several years. It raised nearly $300 million in May 2026 through a public offering, which added shares. More equity raises could reduce each current share's claim on future upside.
Partner economics disappoint
Medium impact · Medium oddsThe Elevar deal reduced pressure on Relay, but future value depends on Elevar developing lirafugratinib well. Milestones and royalties are only useful if the drug advances and sells. If Elevar slows the program, Relay's upside from that asset falls.
Platform promise stays unproven
High impact · Medium oddsRelay's Dynamo platform is meant to find drugs for targets that were hard to drug before. The market will not give full credit for that idea until it produces approved medicines. The Genentech termination of RLY-1971 shows that platform programs can still fail or be dropped.
In one breath
Does Relay Therapeutics have an approved drug?
No. Relay is a clinical-stage company, so its drugs are still in testing. Its future depends on clinical trials, regulatory review, and possible partnerships.
What is zovegalisib?
Zovegalisib, also called RLY-2608, is Relay's lead PI3Kα inhibitor. It is being tested mainly in PIK3CA-mutant HR+/HER2- advanced breast cancer, and also in PROS.
Why did the Elevar deal matter?
Relay licensed lirafugratinib to Elevar in December 2024. That let Relay focus more capital and attention on zovegalisib while keeping possible milestone and royalty upside.
What should investors watch next?
The biggest items are ReDiscover-2 progress, more zovegalisib combination data, PROS trial updates, and cash use. These will show whether Relay's lead drug can carry the company.
